Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis

Novel regimens combining bedaquiline and pretomanid with either linezolid (BPaL regimen) or moxifloxacin and pyrazinamide (BPaMZ regimen) shorten the treatment duration needed to cure tuberculosis (TB) in BALB/c mice compared to that of the first-line regimen and have yielded promising results in in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jian, Li, Si-Yang, Almeida, Deepak V., Tasneen, Rokeya, Barnes-Boyle, Kala, Converse, Paul J., Upton, Anna M., Mdluli, Khisimuzi, Fotouhi, Nader, Nuermberger, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496099/
https://www.ncbi.nlm.nih.gov/pubmed/30833432
http://dx.doi.org/10.1128/AAC.00021-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6496099/
https://www.ncbi.nlm.nih.gov/pubmed/30833432
http://dx.doi.org/10.1128/AAC.00021-19

Ejemplares similares